Mold-Tek Packaging Limited — PPTs, 19-05-2025: Investor Presentation

1. Financial Highlights:

Mold-Tek Packaging’s FY25 revenue grew 12% to Rs. 781.32 Cr, with Q4 revenue up 15% to Rs. 202.61 Cr. EBITDA rose 7% to Rs. 143.86 Cr for the year, though margins slightly compressed to 18.41%. Q4 EBITDA increased 9% to Rs. 39.08 Cr. PAT declined 9% for both FY25 and Q4, impacted by higher depreciation and finance costs. Volume grew 7.3% annually to 38,264 MT, driven by strong sales in Paints and Food segments; Lubricants saw a minor decline.

2. Strategic Initiatives & Growth Drivers:

Capacity expanded by 50% for In-Mold Labeling (IML) via new flexographic machines, targeting Food & FMCG demand. Pharma vertical broke even within a year, with plans to double capacity and introduce tamper-evident, child-resistant packs using clean-room facilities. Continued emphasis on backward integration and higher recycled polypropylene usage aims to improve margins and sustainability.

3. Business Developments:

Enhanced plant capacities in Cheyyar, Panipat, and Satara serve major clients including Aditya Birla and APIL. Launched new beverage, nutritional powder, and patented square packs for ready-to-eat and detergent markets. Pharma segment expanded product launches and export orders, aided by rigorous client audits. Tool room innovations support rapid, specialized packaging development.

4. Market Position & Competitive Advantage:

Maintains leadership in rigid plastic packaging with marquee clients like Asian Paints, Shell, and HUL. Backward integration supports strong margins. ISO-certified pharma unit with DMF approvals and patented designs drive differentiation. Over 200 awarded product concepts and 2 mold patents highlight its deep design capabilities and scale advantage.

5. Investor Implications:

Steady volume/revenue growth and pharma capacity ramp-up indicate positive growth potential. Margin pressure from higher costs requires monitoring, though sustainability efforts and innovation support long-term profitability. Execution risks include scaling pharma exports and market share retention amid economic challenges. Diverse verticals and robust technical moat favor resilient performance going forward.